Novartis to acquire Myricx Bio for up to $1.5bn

2 min read

Novartis has signed an agreement to acquire Myricx Bio in a transaction valued at up to $1.5 billion, comprising a $1.1 billion upfront payment and up to $400 million in milestone payments. Myricx develops antibody-drug conjugates using N-myristoyltransferase inhibitor (NMTi) payloads, which in preclinical data may be active across solid tumours and against tumours resistant to topoisomerase 1 inhibitors. Novartis says the platform could broaden ADC use across multiple tumour settings, and the company expects the deal to close in the second half of 2026 pending regulatory approvals and customary closing conditions.

Novartis acquires NMTi ADC platform for up to $1.5 billion.